Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy.

Daniel den Hoed Cancer Center, Rotterdam, Netherlands.

Survival: monthsCountry:Netherlands
Toxiciy Grade:5City/State/Province:Rotterdam
Treatments:ChemotherapyHospital:Daniel den Hoed Cancer Center
Drugs:Journal:Link
Date:Nov 2012

Description:

Patients:
This study involved metastatic castration-resistant prostate cancer patients with metastases to the bone who were divided into two separate treatment groups. There were 301 patients in group A with a median age of 69 years. Group B had 291 patients with a median age of 68 years.


Treatment:
Patients in group A were treated with the chemotherapy agent docetaxel.
Patients in group B were treated with docetaxel and the drug risedronate, which inhibits bone resorption (degradation).

Toxicities:
There were two treatment-related deaths due to infection in group A. Grade 3-4 diarrhea and neurotoxicity were also reported.

The most severe toxicities were of grade 4 and included grade 3-4 neutropenia and neurotoxicity.

Results:
The median overall survival for groups A and B was 18.4 and 19.2 months, respectively.

Support:
This study was supported by Sanofi-Aventis, makers of risedronate.

Correspondence: Dr. H.J. Meulenbeld; email: [email protected]



Back